A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

Prior to joining GATC Health, Mark spent eight years with Hermes Advisors, an equity hedge fund known for its elite track record. At GATC Health, Mark will spearhead global business development ...

Real Madrid will be aiming to bounce back to winning ways in La Liga when they face Celta Vigo away at Balaidos on Friday night.Following consecutive league defeats against Osasuna and Getafe, Los ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and ...

Astellas Pharma Inc has announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review of its zolbetuximab Biologics License Application (BLA). If approved, the ...

(NASDAQ:ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual ...

The summer transfer window is drawing closer and rumours are intensifying. It is no surprise that top clubs like FC Barcelona ...

Ocugen maintains its guidance to submit a rolling Biologics License Application (BLA) for OCU400 in the third quarter of 2026. A rolling submission allows the company to present completed sections of ...

ImmunityBio has delivered compelling evidence that its flagship therapy, ANKTIVA, is achieving significant commercial traction. While regulatory approvals in Europe and robust clinical data have ...

Year Ended December 31, 2025NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today ...